CMND — Clearmind Medicine Share News
0.000.00%
Last trade - 00:00Brief: Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months
Brief: Clearmind Medicine Announces Successful Completion Of Second Cohort Enrollment
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Clearmind Medicine Inc Files For Offering Of Up To 16 Million Common Shares - SEC Filing
Brief: Clearmind Medicine Advances Cmnd-100 To Dosing Phase At Hadassah Medical Center
Brief: Clearmind Advances Alcoholism Treatment with Positive Data, DSMB Approval, and New Trial Site
Brief: Clearmind Medicine Announces Positive Top-Line Results From First Cohort Of Its FDA-Approved Phase I/Iia Clinical Trial For Alcohol Use Disorder
Brief: SciSparc-Clearmind Collaboration Leads to Publication of U.S.Patent Application Targeting Binge Behavior Disorders
Brief: Clearmind Medicine Secures $10 Million Securities Purchase Agreement To Explore Strategic Opportunities
Brief: Scisparc-Clearmind File International Patent for Novel Obesity & Blood Sugar Therapy
Brief: Clearmind Medicine Receives IRB Approval For Phase 1/2a Clinical Trial For Alcohol Use Disorder
Brief: Clearmind Medicine Files International Patent Application For Novel Combination Therapy Targeting Weight Loss And Fatty Liver Disease
Brief: Scisparc-Clearmind Collaboration Leads To Filing Of International Patent Application For Novel Combination Therapy Targeting Weight Loss And Fatty Liver Disease
Brief: Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
Brief: Clearmind Medicine Announces Enrollment Of First Patient In Phase I/Iia Clinical Trial For Alcohol Use Disorder Treatment